BioSpace News Archive

Mateon Therapeutics, Inc. – Mateon announced that EdgePoint AI, a division within Mateon, announced its decision to expand its manufacturing AI vision camera grid to encompass a contact tracing application which will monitor the spread of COVID-19 indoors.

Centogene N.V. announced that it will issue a press release reporting its financial results for the three months ended March 31, 2020 on Monday, June 15, 2020, and will host a conference call to discuss these results at 8 a.m. EST that day.

TriSalus Life Sciences, a company committed to transforming outcomes for patients with solid tumors, announces the appointment of Scott Davie to the role of Chief Technology Officer, deepening the company’s leadership capabilities as it builds an integrated therapeutic/drug delivery portfolio.

National Blood Donor Week is an opportunity to extend heartfelt thanks to all donors and partners across the country for their commitment, agility and lifesaving contributions to Canada’s Lifeline during the COVID-19 pandemic and throughout the year.

Arch Biopartners Inc. announced it has submitted an Investigational New Drug Application to the U.S. Food and Drug Administration for its lead drug Metablok to conduct a Phase II trial to prevent acute organ inflammation and injury experienced by patients with COVID-19.

Bio-Techne Corporation announced the release of GMP ProDots™ Proteins to support cell and gene therapy manufacturing workflows.

Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), an online provider of healthcare information, professional training and educational services to healthcare professionals and the public in China , announced today that it has engaged with WentzMiller Global Services LLC (“WentzMiller”) to assist its efforts in distributing self-m

MindMed Is Collaborating on a Phase 2 Clinical Trial of LSD For Cluster Headaches with University Hospital Basel’s Liechti Lab

TEGSEDI is the first antisense oligonucleotide medicine available to hATTR patients with polyneuropathy in Italy for at-home subcutaneous injection

Jazz Pharmaceuticals plc announced that Jazz Investments I Limited, its wholly-owned subsidiary, intends to offer, subject to market conditions and other factors, $850 million aggregate principal amount of exchangeable senior notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.